You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Pakistan launches phase-III trial for Covid-19 vaccine developed by China

The vaccine is being developed by China's CanSino Biologics and Pakistan is among the seven countries which will carry out the phase-III trials

Topics
Pakistan  | China | Coronavirus Vaccine

Press Trust of India  |  Islamabad 

Coronavirus, vaccine, covid, drugs, Sepsivac, clinical trials
The NCOC in a statement said that Pakistan''s National Institute of Health (NIH) had partnered with CanSino to carry out the phase-III trials on humans.

on Tuesday announced the launch of the phase-III clinical trials for a potential COVID-19 vaccine being developed by a Chinese company.

Minister of Planning Asad Umar, who also heads the National Command and Operation Centre (NCOC) -- a centralised body set up to coordinate the national COVID-19 response, said about 8,000 to 10,000 Pakistanis will participate in the trials.

The vaccine is being developed by China's CanSino Biologics and is among the seven countries which will carry out the phase-III trials.

"Just launched the phase 3 trials for a Covid19 vaccine in Vaccine has been developed by a Chinese company. A total of 40,000 people will participate in this trial in 7 countries, of which 8 to 10, 000 will be Pakistani," Umar tweeted.

Initial results are expected in four to six months, he added.

The NCOC in a statement said that Pakistan's National Institute of Health (NIH) had partnered with CanSino to carry out the phase-III trials on humans.

Trials for phase 1 and 2 were held in China, it said.

The NIH Executive Director Maj Gen Aamer Ikram termed it an important step for Pakistan to become a part of the trial.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, September 22 2020. 20:43 IST
RECOMMENDED FOR YOU